|Bid||47.76 x 900|
|Ask||47.79 x 900|
|Day's Range||47.71 - 49.43|
|52 Week Range||36.05 - 70.82|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||2.77|
|Expense Ratio (net)||0.95%|
Read a comparison of BIB and LABU and a description of the characteristics and historical performance of these leveraged biotech ETFs.
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Stocks in the biotech sector pose a problem for a swing trade. We take profits quicker, so we need to avoid big losses. Biotech stocks make that difficult.
All three major biotechnology ETFs—the SPDR S&P Biotech ETF (XBI), the iShares NASDAQ Biotechnology Index (IBB), and the ProShares Ultra Nasdaq Biotechnology ETF (BIB)—have posted returns of ~1% in last month, starting on August 10. That compares unfavorably with the performance of the SPDR S&P 500 ETF (SPY), which returned ~1.7% in the same period.